MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
- Written by PR Newswire
SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorization approval by National Medical...
Read more: MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China














